Dramatic Growth of a Vestibular Schwannoma After 16 Years of Postradiosurgery Stability in Association With Exposure to Tyrosine Kinase Inhibitors

Author:

Carlstrom Lucas P.,Muñoz-Casabella Amanda,Perry Avital,Graffeo Christopher S.,Link Michael J.

Abstract

Background: Vestibular schwannoma (VS) is a benign nerve-sheath tumor that sporadically displays aggressive behavior – often attributable to intrinsic tumor biology and an unfavorable immune microenvironment. However, the potential for idiosyncratic responses on VS growth to novel biologics is largely unknown. Methods: Case report. Results: A 57-year-old man underwent stereotactic radiosurgery (SRS) for a small intracanalicular presumed VS, which presented with left-sided hearing loss and episodic vertigo. Treatment response was excellent, with >50% reduction in tumor volume and confirmed stability at 14 years post-SRS radiographic follow-up. The patient subsequently developed an unrelated metastatic gastrointestinal tumor, and was started on tyrosine kinase inhibitors. Within 12-months of regorafenib treatment, and 16-years since SRS, the patient developed ipsilateral House-Brackmann Grade IV facial weakness. Dramatic VS expansion from 14 to 25 mm in maximum diameter, with new brain stem compression, was seen on MRI. Due to poor prognosis of his gastrointestinal malignancy, he declined surgical resection, and elected for palliative salvage SRS. Conclusion: We report the case of VS with radiographically proven stability for >14 years that underwent dramatic tumor progression after treatment with tyrosine kinase inhibitors. The dynamics between systemic immunomodulation and VS disease phenotype remain incompletely understood, and there may be potential for unintended iatrogenic VS progression.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference16 articles.

1. Genetic landscape of sporadic vestibular schwannoma;Håvik;J Neurosurg,2018

2. Macrophage density predicts facial nerve outcome and tumor growth after subtotal resection of vestibular schwannoma;Graffeo;J Neurol Surg B: Skull Base,2018

3. Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma;Perry;J Neurosurg,2019

4. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy;Pottier;Cancers (Basel),2020

5. Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas;de Vries;Otol Neurotol: official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology,2013

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3